Close Menu

There are myriad targets that have been deemed undruggable and they "have rankled even the best-funded laboratories over the years," The Scientist says. However, some biotechs are game for taking those impossible targets on — and they appear to be seeing some success. The Scientist notes that one of those companies, Anchor Therapeutics, is working on targeting membrane receptors for Novartis and Ortho-McNeil-Janssen Pharmaceuticals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

As we enter conference season, Nature News asks why graduate students and postdocs are sometimes forced to choose between paying the rent and paying to attend important meetings.

A new analysis says that a 2018 study claiming to show biparental mtDNA inheritance has several flaws.

In PNAS this week: a genome sequence analysis of Crucihimalaya himalaica, multicellularity and fruiting body development in mushroom-forming fungi, and more.

Two researchers are calling for education for scientists on defending facts.